Goldenrod Therapeutics, Inc.
PrivateLast Round
Seed
Jun 3, 2026
Company Overview
Goldenrod Therapeutics, Inc. is a biotechnology company developing next-generation, brain-penetrant phosphodiesterase 4 (PDE4) inhibitors for serious neurological disorders.
Sector
Healthcare & Life Sciences
Verticals
Biotechnology, Drug Discovery, Clinical Trials
Business Model
B2B
Customer Profile
Revenue Share, Government Contracts
AI Layer
Non-AI
Keywords
Historical Pricing
Historical view of private secondary pricing and transaction trends.
Goldenrod Therapeutics, Inc. Comps
Public and private peers based on sector, stage, and business model.
Goldenrod Therapeutics, Inc. Funding Rounds
Historical fundraising activity
| Round | Date | Amount Raised | Valuation | Investors | Sources |
|---|---|---|---|---|---|
| Seed | Jun 3, 2026 |
Goldenrod Therapeutics, Inc. Investors
Notable investors and investment history
| Investor | Rounds |
|---|---|
| Fannin Innovation Studio | Seed |
Market signals
Structured signals derived from secondary market and firmographic data.
- Jun 3, 2026
$3.2M seed round completed.
Goldenrod Therapeutics, Inc. Filings
SEC and related filings with document metadata.
| Typed | Date | Amount Offered | Amount Sold | Filling | Pages | Download |
|---|---|---|---|---|---|---|
Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation |
Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation |
Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation |
Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation |
Frequently Asked Questions
Common questions about Goldenrod Therapeutics, Inc.'s valuation, stock price, and market status.
